Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells
Noelia Arroyo, Laura Villamayor, Irene Díaz, Rita Carmona, Mireia Ramos-Rodríguez, Ramón Muñoz-Chápuli, Lorenzo Pasquali, Miguel G. Toscano, Franz Martín, David A. Cano, Anabel Rojas
Noelia Arroyo, Laura Villamayor, Irene Díaz, Rita Carmona, Mireia Ramos-Rodríguez, Ramón Muñoz-Chápuli, Lorenzo Pasquali, Miguel G. Toscano, Franz Martín, David A. Cano, Anabel Rojas
View: Text | PDF
Research Article Cell biology Gastroenterology

GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells

  • Text
  • PDF
Abstract

In response to liver injury, hepatic stellate cells activate and acquire proliferative and contractile features. The regression of liver fibrosis appears to involve the clearance of activated hepatic stellate cells, either by apoptosis or by reversion toward a quiescent-like state, a process called deactivation. Thus, deactivation of active hepatic stellate cells has emerged as a novel and promising therapeutic approach for liver fibrosis. However, our knowledge of the master regulators involved in the deactivation and/or activation of fibrotic hepatic stellate cells is still limited. The transcription factor GATA4 has been previously shown to play an important role in embryonic hepatic stellate cell quiescence. In this work, we show that lack of GATA4 in adult mice caused hepatic stellate cell activation and, consequently, liver fibrosis. During regression of liver fibrosis, Gata4 was reexpressed in deactivated hepatic stellate cells. Overexpression of Gata4 in hepatic stellate cells promoted liver fibrosis regression in CCl4-treated mice. GATA4 induced changes in the expression of fibrogenic and antifibrogenic genes, promoting hepatic stellate cell deactivation. Finally, we show that GATA4 directly repressed EPAS1 transcription in hepatic stellate cells and that stabilization of the HIF2α protein in hepatic stellate cells leads to liver fibrosis.

Authors

Noelia Arroyo, Laura Villamayor, Irene Díaz, Rita Carmona, Mireia Ramos-Rodríguez, Ramón Muñoz-Chápuli, Lorenzo Pasquali, Miguel G. Toscano, Franz Martín, David A. Cano, Anabel Rojas

×

Figure 2

Lineage tracing of G2-Cre–derived cells and Gata4 expression during adult liver fibrosis and recovery.

Options: View larger image (or click on image) Download as PowerPoint
Lineage tracing of G2-Cre–derived cells and Gata4 expression during adul...
(A–O) Liver sections of G2-Cre;Rosa26ReYFP adult mice. Immunostaining for (A, F, and K) YFP and (B, G, and L) GATA4 in liver sections of mice treated with vehicle (oil) (A and B) and CCl4 for 4 weeks (F and G) and 1 month after CCL4 treatment (recovery phase) (K and L). (C, H, and M) Merged images of YFP, GATA4, and DAPI staining. Polarized light microscopy images of Sirius red–stained liver sections of (D) mice treated with oil, (I) mice treated with CCl4, and (N) mice 1 month after recovery. (A–L, n = 3 each group). Immunostaining for collagen IV in liver sections of (E) mice treated with oil, (J) mice treated with CCl4, and (O) mice 1 month after recovery. (P) Quantification of double GATA4/YFP-positive cells per total GATA-positive cells in livers of each experimental group (n = 3–5 each group). (Q) Relative quantification of Sirius red–stained area per total liver area in each experimental group (n = 3–4 each group). (R) Relative quantification of collagen IV–stained area per total liver area in each experimental group (n = 3 each group). The no injury group denotes mice not injected with adenovirus or CCL4. Quantitative RT-PCR analysis of (S) Gata4, (T) Col1A1, and (U) α-Sma expression in each experimental group (n = 3–5 each group). (V) Western blot analysis of GATA4, collagen IV, and α-SMA accumulation in livers of mice treated with oil, mice treated with CCl4, and mice 1 month after recovery. β-Actin protein or GAPDH was used for loading control. Samples from 3 independent mice in each experimental group are shown. Scale bars: 25 μm (A–C, F–H, K–M, E, J, and O); 100 μm (D, I, and N). Statistical analyses was performed using 1-way ANOVA. Error bars represent mean ± SEM.*P < 0.05. **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts